Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma

NCT00022607 is registered in ClinicalTrials.gov with California Cancer Consortium as lead sponsor.

NCT NCT00022607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma
Lead sponsor
California Cancer Consortium
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2002
Completion date
May 31, 2006
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm